Company Description
Barrier Therapeutics wants to come between you and some nasty fungi. The company's diaper rash cream, sold in the US as Vusion, is its top...
Key Barrier Therapeutics Financials
| Company Type | Public - NASDAQ (GM): BTRX Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $24.1 |
| 2005 Employees | 89 |
More Barrier Therapeutics Financials (11 pages)
Latest Barrier Therapeutics Jobs jobs by Indeed
Competition
Competitive Landscape for Pharmaceutical Manufacture and Sale
The industry is marked by rapid advances in scientific knowledge that produce ever-more effective medicines. Profitability is determined mainly by the ability to discover new drugs....
Read more about Barrier Therapeutics's competition across multiple industries
Top Barrier Therapeutics Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Barrier Therapeutics Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| CEO and Director | Alfred (Al) Altomari | Network | E-mail |
| Director Business Development | Gerrit Dispersyn | Network | E-mail |
| VP Finance and CFO | Dennis P. Reilly | Network | E-mail |
More Barrier Therapeutics Executives
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Barrier Therapeutics News
- Closing Update: Broadly Firmer Close in Wake of Fed Statement, Tech Advance [Midnight Trader] (25 Jun 2008 16:13:00 EDT)
- Stocks Headed for Green Ahead of Fed Meeting Conclusion, Big Name Earnings [Midnight Trader] (25 Jun 2008 09:03:00 EDT)
- Analyst Actions: Barrier Therapeutics Slips, Reportedly Downgraded [Midnight Trader] (25 Jun 2008 08:07:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.